Celsion Corporation to Report Clinical Trial Update of ThermoDox(r) in Recurrent Chest Wall Breast Cancer Study at the Society for Thermal Medicine 2009 Annual Meeting

COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN) today announced that clinical data from its ThermoDox® Phase 1 Recurrent Chest Wall (RCW) Breast Cancer study will be presented by Duke University Medical Center researchers at the Society for Thermal Medicine 2009 Annual Meeting in Tucson, Arizona on April 3-7, 2009. The presentation will provide updated safety, dosing, and local response profiles in patients with RCW breast cancer treated with ThermoDox® in combination with microwave hyperthermia, or heat.